natgillin/translations-raw huggingface dataset:
Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively.
mgdvakrat na dan) z atazanavirjem in ritonavirjem(300/100 mg enkrat na dan) se je pri zdravihpreiskovancihCmaxatazanavirja povečala v povprečjuza 1,5-krat, njegova AUC paza 2,5-krat (razponod 0,9-krat do 4,1-krat).
9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days.
9 od 11 bolnikov so uspešno zdravili s peroralno suspenzijo posakonazola 800 mg/dan v deljenihodmerkih.
Discontinuation of Posaconazole Accord should be considered if clinical signs and symptoms are consistent with development of liver disease.
Spremljanje bolnika mora vključevatilaboratorijskoocenodelovanjajeter(šeposebejjetrnetesteindoločanjebilirubina).Če klinični znaki in simptomi kažejo na razvoj jetrne bolezni, je treba po potrebi prekiniti zdravljenje z zdravilom Posakonazol Accord.
Concomitant use of posaconazole and efavirenz should be avoided unless the benefit to the patient outweighs the risk.
%.Sočasni uporabi posakonazola in efavirenza se je treba izogibati, razen če korist za bolnika odtehta tveganje.
Thereafter blood levels of ciclosporin should be monitored carefully during co-administration, and upon discontinuation of posaconazole treatment, and the dose of ciclosporin should be adjusted as necessary.
Potem je treba natančno spremljati koncentracije ciklosporina v krvi, in sicer med sočasno uporabo in po prenehanju zdravljenja s posakonazolom;
When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose).
Ob uvedbi zdravljenja s posakonazolomjetrebabolnikom,kižeprejemajotakrolimus,odmerektakrolimusazmanjšati(npr.napribližn otretjinotrenutnega odmerka).
What Posaconazole Accord contains The active substance is posaconazole.
Zdravilo Posakonazol Accord vsebuje učinkovino posakonazol.
oedema, pain, chills, malaise, chest discomfort, drug intolerance, feeling jittery, mucosal inflammation
edemi, bolečine, mrzlica, splošno slabo počutje, nelagodje v prsnem košu, neprenašanje zdravila, občutek živčnosti,
Posaconazole therapy was given for a median duration of 28 days.
Srednji čas zdravljenje s posakonazolom je bil 28 dni.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
7-dnevnem predhodnem zdravljenju s terapevtskimi odmerki učinkovitega antimikotičnega zdravila.
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4.
Posakonazollahkobistveno povečaplazemskokoncentracijozaviralcevreduktazeHMG-CoA, ki sepresnovijo s CYP3A4.
Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly.
Koncentracijo sirolimusa je treba izmeriti ob uvedbi zdravljenja, med sočasno uporabo in tudi ob ukinitvi zdravljenja s posakonazolom in po potrebi ustrezno prilagoditi odmerke sirolimusa.Zavedatise je treba, da se med sočasno uporabo sirolimusa in posakonazola spremeni razmerje med najnižjo koncentracijo sirolimusa in njegovo AUC.
Exposures after tablet administration are generally higher than, but overlapping with, exposures after administration of posaconazole oral suspension.
Izpostavljenost je po uporabi tablet na splošno večja kot po uporabi peroralne suspenzije posakonazola, vendar pa se ena in druga prekrivata.
Summary of the safety profile
Povzetek varnostnega profila Tablete posakonazola
The most frequently reported serious related adverse reactions included nausea, vomiting, diarrhoea, pyrexia, and increased bilirubin.
Med najpogosteje poročanimi resnimi, z zdravilom povezanimi neželenimi učinki so bili navzea, bruhanje, driska,
Summary of posaconazole tablet bridging study
Povzetek premostitvene študije s tabletami posakonazola
Multiple, time-matched ECGs collected over a 12 hour period were obtained before and during administration of posaconazole oral suspension (400 mg twice daily with high fat meals) from 173 healthy male and female volunteers aged 18 to 85 years.
Ocena elektrokardiograma 173 zdravim prostovoljcem in prostovoljkam, starim od 18 do 85 let, so v 12-urnem obdobju posneli več časovno usklajenih EKG, in sicer pred in med uporabo peroralne suspenzije posakonazola (400 mg dvakrat na dan, zaužite z zelo mastno hrano).
it was the period from first dose to last dose of study medicinal product plus 7 days.
v študiji316pa je bilo to obdobje od prvega odmerka do zadnjega odmerka preučevanega zdravila plus
hepatocellular damage, hepatitis, jaundice, hepatomegaly, cholestasis, hepatic toxicity, hepatic function abnormal
holestaza, hepatotoksičnost, nenormalno delovanje jeter
renal tubular acidosis, interstitial nephritis Reproductive system and breast disorders Uncommon:
ledvična tubularna acidoza, intersticijski nefritis
Cav = the average concentration when measured at steady state *20 patients received 200 mg once daily (Day 1 200 mg twice daily)
*20 bolnikov je prejemalo 200 mg enkrat na dan (200 mg dvakrat na dan1.dan)
If you become pregnant while you are taking Posaconazole Accord, contact your doctor straight away.
Če med jemanjem zdravila Posakonazol Accord zanosite, se nemudoma posvetujte z zdravnikom.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 100 mg of posaconazole.
Ena gastrorezistentna tableta vsebuje 100 mg posakonazola.
What Posaconazole Accord is and what it is used for
Kaj je zdravilo Posakonazol Accord in za kaj ga uporabljamo
Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
Zdravilo Posakonazol Accord je indicirano tudi za profilakso invazivnih glivnih okužb pri: - bolnikih, ki prejemajo kemoterapijo za doseganje remisije akutne mieloične levkemije (AML)
Gastrointestinal dysfunction
Profilaksainvazivnihglivniho kužb
vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth, flatulence, constipation, anorectal discomfort
bruhanje, bolečine v trebuhu, driska, dispepsija, suha usta,
Posaconazole Accord should be administered with caution to patients with pro-arrhythmic conditions such as: - Congenital or acquired QTc prolongation - Cardiomyopathy, especially in the presence of cardiac failure - Sinus bradycardia - Existing symptomatic arrhythmias - Concomitant use with medicinal products known to prolong the QTc interval (other than those mentioned in section 4.3).
- obstoječe simptomatske aritmije, - sočasna uporaba z zdravili, za katera je znano, da podaljšajo interval QTc (razen tistih, ki so omenjena v poglavju 4.3).
Posaconazole Accord contains a medicine called posaconazole.
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Posakonazol Accord
altered medicine levels, blood phosphorus decreased, chest x-ray abnormal * Based on adverse reactions observed with the oral suspension, gastro-resistant tablets, and concentrate for solution for infusion.
* Na podlagi neželenih učinkov, opaženih s peroralno suspenzijo, gastrorezistentnimi tabletami in koncentratom za raztopino za infundiranje.
This finding was not seen in monkeys dosed for one year.
dosežene med uporabo terapevtskih odmerkov pri človeku, se je pojavila fosfolipidoza nevronov.Tega niso opazili pri opicah, ki so zdravilo dobivale eno leto.
Do not breast-feed while taking Posaconazole Accord.
Med jemanjem zdravila Posakonazol Accord ne dojite.
- if you have an abnormal heart rhythm tracing (ECG) that shows a problem called long QTc interval - if you have a weakness of the heart muscle or heart failure - if you have a very slow heartbeat - if you have heart rhythm disturbance - if you have any problem with potassium, magnesium or calcium levels in your blood - if you are taking vincristine, vinblastine and other “vinca alkaloids” (medicines used to treat cancer).
- srčno popuščanje ali srčni infarkt, ki lahko povzroči zastoj srca in smrt; motnje srčnega ritma z nenadno smrtjo - krvni strdki v nogah (globoka venska tromboza) - med znaki so močne bolečine ali oteklost nog
Posaconazole oral suspension External control group
Zunanja kontrolna skupina
Sixteen patients 8-17 years of age were treated with posaconazole oral suspension 800 mg/day in a study for invasive fungal infections.
Šestnajst bolnikov, starih od 8 do 17 let, so v študiji invazivnih glivnih okužb zdravili s peroralno suspenzijo posakonazola v odmerku mg/dan.Napodlagirazpoložljivihpodatkovza16odtehpediatričnih bolnikov je varnostniprofilzdravila videti podoben kot pri bolnikih,starih ≥18 let.
Breast-feeding
nizoldipin)
There is insufficient data among different races with posaconazole tablets.
O uporabi tablet posakonazola pri različnih rasah ni dovolj podatkov.
Posaconazole plasma concentrations following administration of posaconazole tablets are generally higher than those obtained with posaconazole oral suspension.
Koncentracije posakonazola vplazmi so po uporabi tablet običajno večje kot po uporabi peroralnesuspenzije.
high or low blood pressure - low blood pressure - inflammation of the pancreas (pancreatitis) - this may cause severe stomach pain - oxygen supply to the spleen is interrupted (splenic infarction) - this may cause severe stomach pain - severe kidney problems - signs include passing more or less urine, that is a different colour than usual - high blood levels of creatinine - shown in blood tests - cough, hiccups - nose bleeds - severe sharp chest pain when breathing in (pleurritic pain) - swelling of lymph glands (lymphadenopathy) - reduced feeling of sensitivity especially on the skin - tremor - high or low blood sugar levels - blurred vision, sensitivity to light - hair loss (alopecia) - mouth ulcers - shivering, feeling generally unwell - pain, back or neck pain, pain in arms or legs - water retention (oedema) - menstrual problems (abnormal vaginal bleeding)
- hude težave z ledvicami - med znaki so izločanje več ali manj urina, ki je drugačne barve kot po navadi - visoka koncentracija kreatinina v krvi - pokaže se na preiskavah krvi - kašelj, kolcanje - krvavitve iz nosu
Common: the following may affect up to 1 in 10 people - a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak - abnormal skin sensations, such as numbness, tingling, itching, creeping, pricking or burning - headache - low potassium levels - shown up in blood tests - low magnesium levels - shown up in blood tests - high blood pressure - loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste - heartburn (a burning sensation in the chest rising up to the throat) - low levels of “neutrophils” a type of white blood cell (neutropenia) -this can make you more likely to get infections and be shown up in blood tests - fever - feeling weak, dizzy, tired or sleepy - rash - itching - constipation - rectal discomfort
- glavobol - nizka koncentracija kalija - pokaže se na preiskavah krvi - nizka koncentracija magnezija - pokaže se na preiskavah krvi - visok krvni tlak - izguba apetita, bolečine v želodcu ali razdražen želodec, vetrovi, suha usta, spremembe okusa
Moreover, sparse PK samples were collected at several days during steady state before the next dose (Cmin) for a larger subject population.
Poleg tega so redko razporejenefarmakokinetične vzorce odvzeli ob več dneh v stanju dinamičnega ravnovesja pred naslednjim odmerkom (Cmin) zavečjo populacijo preiskovancev.Na podlagi povprečnihkoncentracij Cminje bilomogoče za 186 preiskovancev, ki so prejemali 300mg,izračunatipredvidenopovprečno koncentracijo (Cav).
If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood.
Učinek posakonazola na sirolimus pri bolnikih ni znan, vendar je treba pričakovati, da jespremenljiv zaradi spremenljive izpostavljenosti posakonazolumedbolniki.Sočasnauporabaposakonazola s sirolimusom ni priporočljiva in se ji je treba izogniti, če jele mogoče.Česesočasniuporabi ni mogoče izogniti, je ob uvedbi zdravljenja s posakonazolom priporočljivo zelo zmanjšati odmerek sirolimusa in zelo pogosto preverjati najnižjo koncentracijo sirolimusa v polni krvi.
No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure.
Eliminacijski razpolovni čas (t1/2) se jev zadevnih skupinah podaljšal s približno 27 urnavsedopribližno43ur.Bolnikom z blagodohudookvaro jeter odmerka sicer ni trebaprilagoditi, a je zaradi možne večje plazemske izpostavljenosti priporočljiva previdnost.
Vascular disorders Common:
Žilne bolezni Pogosti:
hepatic failure, hepatitis cholestatic, hepatosplenomegaly, liver tenderness, asterixis Skin and subcutaneous tissue disorders Common:
odpoved jeter, holestatski hepatitis, hepatosplenomegalija,
See also below regarding the effect of posaconazole on rifabutin plasma levels.
Glede vpliva posakonazola na koncentracijerifabutina vplazmi glejtetudispodaj.
Gastrointestinal disorders Very Common:
Bolezni prebavil Zelo pogosti:
− sudden, severe allergic reaction.
- nenadna, huda alergijska reakcija.
In the absence of compatibility studies, INTEGRILIN must not be mixed with other medicinal products except those mentioned in 6.6.
Zaradi pomanjkanja študij kompatibilnosti zdravila INTEGRILIN ne smemo mešati z drugimi zdravili, razen s tistimi, ki so našteta v poglavju 6.6.
− Integrilin is not intended for use in children or adolescents less than 18 years of age.
− Zdravilo Integrilin ni namenjeno za uporabo pri otrocih in mladostnikih do 18. leta starosti.
INTEGRILIN is not compatible with furosemide.
INTEGRILIN ni združljiv s furosemidom.
− if you have been treated with another medicine of the same type as Integrilin.
− če ste bili zdravljeni z drugim zdravilom iste vrste, kot je Integrilin.
Eptifibatide p-Value
Eptifibatid vrednost p
− anaemia (decreased number of red blood cells).
- anemija (zmanjšano število rdečih krvnih celic).
What Integrilin is and what it is used for
Kaj je zdravilo Integrilin in za kaj ga uporabljamo
According to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance:
Po epidemioloških izsledkih je večja incidenca kardiovaskularnih pojavov povezana z določenimi pokazatelji, npr.: - starostjo,
Other medicines and Integrilin
Druga zdravila in zdravilo Integrilin
Integrilin is not usually recommended for use during pregnancy.
Zdravila Integrilin po navadi ni priporočljivo uporabljati med nosečnostjo.
− Before and during your treatment with Integrilin, samples of your blood will be tested as a safety measure to limit the possibility of unexpected bleeding.
− Pred in med zdravljenjem z zdravilom Integrilin bodo pri vas opravili krvne preiskave kot varnostni ukrep za zmanjšanje možnosti za pojav nepričakovanih krvavitev.
INTEGRILIN should not be used during pregnancy unless clearly necessary.
Zdravila INTEGRILIN ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
− During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected bleeding.
− Med uporabo zdravila Integrilin vas bodo skrbno spremljali, da ugotovijo morebitne znake nenavadne ali nepričakovane krvavitve.
− Integrilin is recommended for use only in adult, hospitalised patients in coronary care units.
− Zdravilo Integrilin priporočamo za uporabo le pri odraslih bolnikih, hospitaliziranih na bolnišničnih koronarnih oddelkih.
INTEGRILIN-treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Tudi pri z zdravilom INTEGRILIN zdravljenih bolnikih, ki so imeli protrombinski čas (PČ) > 14,5 sekund in so sočasno prejemali varfarin, ni kazalo, da bi bili bolj ogroženi zaradi krvavitev.
What Integrilin is and what it is used for What you need to know before you are given Integrilin How to use Integrilin
Kaj je zdravilo Integrilin in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Integrilin Kako uporabljati zdravilo Integrilin
Date of latest renewal: 09.07.2009
Datum prve odobritve: 01.07.1999 Datum zadnjega podaljšanja: 09.07.2009
You must not be given Integrilin: − if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section
− če ste alergični na eptifibatid ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju
Please refer to the Normosol R Summary of Product Characteristics for details on its composition.
glejte Povzetek glavnih značilnosti zdravila Normosol R za podrobnosti o njegovi sestavi.
There were no notable differences observed with GUSTO severe bleeding rates.
Pri deležih hudih krvavitev GUSTO ni bilo opaznih razlik.
Frequencies are defined as very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Blood and Lymphatic System Disorder
Bolezni krvi in limfatičnega sistema
INTEGRILIN is also intended for concurrent use with acetylsalicylic acid, as it is part of standard management of patients with acute coronary syndromes, unless its use is contraindicated.
Zdravilo INTEGRILIN je namenjeno tudi za sočasno uporabo z acetilsalicilno kislino, ker je del standardne sheme vodenja bolnikov z akutnim koronarnim sindromom, če zanj ni kontraindikacij.
− marked ECG changes (in particular ST-segment abnormalities)
- izrazitimi spremembami v EKG (zlasti z nepravilnostmi spojnice ST),
− known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm)
- znano anamnezo intrakranialne bolezni (neoplazme, arteriovenske malformacije, anevrizme);
The mechanism, whether immune- and/or non-immune-mediated, by which eptifibatide may induce thrombocytopaenia is not fully understood.
Mehanizem - imunski in/ali neimunski - po katerem lahko eptifibatid povzroči trombocitopenijo, ni povsem pojasnjen.
PURSUIT trial
Študija PURSUIT
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
INTEGRILIN infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump.
Infuzijo zdravila INTEGRILIN morate nemudoma ustaviti, če nastopijo okoliščine, ki zahtevajo trombolitično zdravljenje, če mora bolnik na nujen koronarni premostitveni poseg ali če potrebuje intraaortno balonsko črpalko.
Your doctor will weigh up the benefit to you against the risk to your baby of using Integrilin while you are pregnant.
Zdravnik bo pretehtal koristi, ki jih uporaba zdravila Integrilin med nosečnostjo pomeni za vas, v primerjavi s tveganjem, ki ga pomeni za otroka.
GUSTO severe/life threatening bleeding was uncommon and comparable in both treatment groups (0.8%).
Hude/smrtno nevarne krvavitve po GUSTO so bile občasne in v obeh terapevtskih skupinah primerljive (0,8 %).
Patients could be enrolled only if they had experienced cardiac ischemia at rest (≥ 10 minutes) within the previous 24 hours and had:
Bolniki so bili lahko v to študijo vključeni le, če so imeli v preteklih 24 urah ishemijo miokarda v mirovanju (≥ 10 minut) in:
If serious bleeding occurs that is not controllable with pressure, the INTEGRILIN infusion should be stopped immediately and any unfractionated heparin that is given concomitantly.
Če se pojavi hujša krvavitev, ki je ni mogoče obvladati s pritiskom, morate nemudoma ustaviti infuzijo zdravila INTEGRILIN in morebitno sočasno uporabo nefrakcioniranega heparina.
In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg.
V isti populaciji je razpolovni čas eliminacije zdravila iz plazme približno 2,5 ur, plazemski očistek od 55 do 80 ml/kg/h, porazdelitveni volumen pa približno 185 do 260 ml/kg.
Cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation.
Pogosti srčni zastoj, ventrikularna fibrilacija, ventrikularna tahikardija, kongestivno srčno popuščanje, atrioventrikularni blok, atrijska fibrilacija
ESPRIT: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation.
ESPRIT: To je bila dvojno slepa, multicentrična, randomizirana, s placebom kontrolirana študija vzporednih skupin za oceno varnosti in učinkovitosti zdravljenja z eptifibatidom pri bolnikih s predvideno neurgentno perkutano koronarno intervencijo (PCI) z namestitvijo žilne opornice.
Glaxo Operations UK Ltd., (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, Co. Durham, DL12 8DT, United Kingdom
Glaxo Operations UK Ltd., (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, Co.Durham, DL12 8DT, Velika Britanija
− reduced blood flow to the brain.
- zmanjšana prekrvavitev možganov.
The need for blood transfusions was increased modestly by Integrilin treatment (11.8% versus 9.3% for placebo).
Zdravljenje z zdravilom Integrilin je zmerno povečalo potrebo po transfuzijah krvi (11,8 % v primerjavi z 9,3 % pri placebu).
Consequently the use of INTEGRILIN is not recommended in these circumstances (see section 4.5).
Uporaba zdravila INTEGRILIN pri takšnih bolnikih torej ni priporočljiva (glejte poglavje 4.5).
During treatment with Integrilin in this study, minor bleeding was a very common complication (>1/10, or 13.1% for Integrilin versus 7.6% for placebo).
Manjše krvavitve so bile v tej študiji med zdravljenjem z zdravilom Integrilin zelo pogost zaplet (> 1/10 ali 13,1 % za zdravilo Integrilin v primerjavi s 7,6 % za placebo).
If either a confirmed platelet decrease to < 100,000/mm3 or acute profound thrombocytopaenia is observed, discontinuation of each treatment medication having known or suspected thrombocytopenic effects, including eptifibatide, heparin and clopidogrel, should be considered immediately.
Če se pojavi potrjeno zmanjšanje števila trombocitov na < 100.000 celic/mm3, ali akutna izrazita trombocitopenija, je treba nemudoma prekiniti uporabo zdravil, za katere je znano ali se domneva, da učinkujejo trombocitopenično, vključno z eptifibatidom, heparinom in klopidogrelom.
Ask your hospital pharmacist how to throw away medicines you no longer use.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte z bolnišničnim farmacevtom.
4.5 Interaction with other medicinal products and other forms of interaction
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Varfarin in dipiridamol